Yi Zhao

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Rheumatoid Arthritis

Prognostic Factors

Ejection Fraction

Top Venues

Expert opinion on drug safety

The Annals of pharmacotherapy

Molecules (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Yi Zhao, Yuzhou Zhang, Lin Yang, Kanghuai Zhang, Sha Li
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System. The Annals of pharmacotherapy (2024)
Yi Zhao, Zelin Li, Kanghuai Zhang, Na Wang
Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. Expert opinion on drug safety (2024)
Yi Zhao, Zelin Li, Kanghuai Zhang, Na Wang
Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. Expert opinion on drug safety (2024)
Yi Zhao, Zelin Li, Kanghuai Zhang, Na Wang
Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. Expert opinion on drug safety 23 (8) (2024)
Yi Zhao, De-Chao Tan, Bo Peng, Lin Yang, Si-Yuan Zhang, Rui-Peng Shi, Cheong-Meng Chong, Zhang-Feng Zhong, Sheng-Peng Wang, Qiong-Lin Liang, Yi-Tao Wang
Neuroendocrine-Immune Regulatory Network of Eucommia ulmoides Oliver. Molecules (Basel, Switzerland) 27 (12) (2022)